Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zolgensma (onasemnogene abeparvovec)
Pharma
Novartis scores FDA approval for new version of SMA gene therapy
Novartis is pricing the one-time intrathecal gene therapy at a wholesale acquisition cost of $2.59 million.
Angus Liu
Nov 25, 2025 10:02am
UPDATED: Most expensive drugs in the US in 2025
Aug 11, 2025 3:00am
Novartis, Sarepta tipped to drive genomic therapy sales boom
May 15, 2025 12:18pm
Novartis peels back Zolgensma IT data in older SMA patients
Mar 19, 2025 9:00am
Roche picks up FDA nod for easier Evrysdi dosing format in SMA
Feb 12, 2025 2:30pm
Novartis readies intrathecal Zolgensma for older SMA patients
Jan 2, 2025 12:30pm
